Vanda Pharmaceuticals (VNDA) Other Non-Current Liabilities (2012 - 2026)

Vanda Pharmaceuticals (VNDA) has 14 years of Other Non-Current Liabilities data on file, last reported at $10.1 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities rose 9.54% year-over-year to $10.1 million; the trailing twelve-month figure through Mar 2026 stood at $10.1 million (up 9.54% YoY), and the FY2025 full-year result was $9.5 million, down 0.56% from the prior year.
• Other Non-Current Liabilities climbed to $10.1 million in Q1 2026, from $9.5 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $11.0 million in Q3 2025 to a low of $1.0 million in Q1 2022.
• A 5-year average of $7.7 million and a median of $8.8 million in 2024 frame the typical range for Other Non-Current Liabilities.
• Across the five-year window, Other Non-Current Liabilities sank 61.09% in 2022 and surged 540.08% in 2023, its largest moves.
• Tracing VNDA's Other Non-Current Liabilities over 5 years: stood at $6.8 million in 2022, then increased by 29.81% to $8.8 million in 2023, then grew by 8.61% to $9.6 million in 2024, then dropped by 0.56% to $9.5 million in 2025, then gained by 6.23% to $10.1 million in 2026.
• Business Quant data shows VNDA's Other Non-Current Liabilities at $10.1 million in Q1 2026, $9.5 million in Q4 2025, and $11.0 million in Q3 2025.